Brokerages expect Repligen Co. (NASDAQ:RGEN) to report $0.16 earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Repligen’s earnings, with the highest EPS estimate coming in at $0.18 and the lowest estimate coming in at $0.14. Repligen posted earnings per share of $0.15 in the same quarter last year, which indicates a positive year-over-year growth rate of 6.7%. The company is expected to issue its next earnings report on Thursday, May 3rd.
On average, analysts expect that Repligen will report full year earnings of $0.70 per share for the current fiscal year, with EPS estimates ranging from $0.68 to $0.72. For the next fiscal year, analysts forecast that the business will post earnings of $0.87 per share, with EPS estimates ranging from $0.82 to $0.92. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Repligen.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. Repligen had a net margin of 20.08% and a return on equity of 7.08%. The business had revenue of $41.60 million during the quarter, compared to analysts’ expectations of $41.13 million. During the same quarter in the prior year, the company posted $0.08 EPS. The business’s revenue for the quarter was up 62.5% on a year-over-year basis.
Shares of Repligen (NASDAQ RGEN) traded down $0.24 during mid-day trading on Tuesday, hitting $35.47. 330,223 shares of the stock traded hands, compared to its average volume of 259,962. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.08 and a current ratio of 9.63. Repligen has a 52-week low of $29.56 and a 52-week high of $46.81. The firm has a market cap of $1,541.72, a price-to-earnings ratio of 49.96, a P/E/G ratio of 2.03 and a beta of 0.91.
In other Repligen news, VP Howard Benjamin sold 12,729 shares of the stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total transaction of $449,842.86. Following the sale, the vice president now directly owns 36,554 shares in the company, valued at approximately $1,291,818.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Anthony Hunt sold 8,970 shares of the stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total transaction of $322,471.50. Following the sale, the chief executive officer now owns 83,613 shares in the company, valued at $3,005,887.35. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in RGEN. SG Americas Securities LLC acquired a new stake in Repligen during the 3rd quarter worth approximately $180,000. Crossmark Global Holdings Inc. acquired a new stake in Repligen during the 3rd quarter worth approximately $241,000. Brown Advisory Inc. acquired a new stake in Repligen during the 3rd quarter worth approximately $310,000. First Manhattan Co. lifted its holdings in Repligen by 16.7% during the 4th quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock worth $380,000 after buying an additional 1,500 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in Repligen during the 4th quarter worth approximately $462,000. Institutional investors own 84.32% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3226501/3226501.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.